Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study (S51.001)
Bibliographic record
Abstract
OBJECTIVE: To examine alemtuzumab’s effect on brain volume loss (BVL) over 5 years in the ongoing CARE-MS extension study (NCT00930553). BACKGROUND: Patients with active relapsing-remitting MS (RRMS) who were treatment-naive (CARE-MS I; NCT00530348) or who had an inadequate response (≥1 relapse) to a prior therapy at baseline (CARE-MS II; NCT00548405) demonstrated improved efficacy outcomes following treatment with alemtuzumab versus SC IFNB-1a over 2 years, including significant slowing of BVL. Efficacy on clinical and MRI endpoints was durable through 5 years. DESIGN/METHODS: Patients who received 2 annual courses of alemtuzumab in the core CARE-MS studies continued in the extension study, in which they could receive as-needed alemtuzumab retreatment for relapse or radiological activity. MRI scans were assessed at baseline and annually thereafter. BVL was derived by relative brain parenchymal fraction change. RESULTS: 349 (95[percnt]) CARE-MS I and 393 (93[percnt]) CARE-MS II alemtuzumab patients entered the extension study. Of those, 91[percnt] and 93[percnt] remained on study, 68[percnt] and 60[percnt] received no alemtuzumab retreatment since the initial 2 courses at core study baseline and Month 12, and 2[percnt] and 8[percnt] received another disease-modifying therapy. Median yearly BVL decreased progressively over 4 years in CARE-MS I, remaining low in Year 5 (Year 1: -0.59[percnt], Year 2: -0.25[percnt], Year 3: -0.19[percnt], Year 4: -0.15[percnt], Year 5: -0.20[percnt]). In CARE-MS II, median yearly BVL slowed over 3 years and remained low in Years 4 and 5 (Year 1: -0.48[percnt], Year 2: -0.22[percnt], Year 3: -0.10[percnt], Year 4: -0.19[percnt], Year 5: -0.07[percnt]). CONCLUSIONS: Slowing of BVL with alemtuzumab was maintained over 5 years, despite most patients not receiving alemtuzumab retreatment for 4 years. Based on these findings, alemtuzumab may provide a unique treatment approach with durable efficacy in the absence of continued treatment for RRMS patients. STUDY SUPPORTED BY: Genzyme, a Sanofi company, and Bayer Healthcare Pharmaceuticals.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".